Sex-specific medication trajectories in older adults newly diagnosed with diabetes.
Diabetes
Latent class models
Medication use
Older adults
Quebec
Sex differences
Journal
Exploratory research in clinical and social pharmacy
ISSN: 2667-2766
Titre abrégé: Explor Res Clin Soc Pharm
Pays: United States
ID NLM: 9918266300706676
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
16
05
2023
revised:
13
06
2023
accepted:
13
06
2023
medline:
6
7
2023
pubmed:
6
7
2023
entrez:
6
7
2023
Statut:
epublish
Résumé
People with diabetes tend to use many medications to treat diabetes and comorbidities. Nevertheless, the evolution of polypharmacy in newly diagnosed males and females has been little studied. The objective of this paper was to identify and describe medication trajectories in incident diabetes cases according to sex. Data were obtained from the Quebec Integrated Chronic Disease Surveillance System. We built a population-based cohort of community-dwelling individuals aged >65 years diagnosed with diabetes in 2014 who were alive and covered with the public drug plan until March 31, 2019. Latent class models were used to identify medication trajectory groups in males and females separately. Of the 10,363 included individuals, 51.4% were males. Females were older and more likely to have more medication claims than males. Four trajectory groups were identified for males and five for females. Most trajectories showed sustained and stable number of medications over time. For each sex, only one of the trajectory groups included a mean annual number of medications lesser than five. Slight increasing trends of medication use were detected in the trajectories composed of very high users, which included older, more comorbid individuals frequently exposed to potentially inappropriate medications. Most males and females with incident diabetes had a high burden of medication following the year of diagnosis and were classified in a group of sustained medication use over time. The largest increase in medication was among those who had higher level of polypharmacy of questionable quality at baseline, raising concerns about the innocuity of such medication trajectories.
Sections du résumé
Background
UNASSIGNED
People with diabetes tend to use many medications to treat diabetes and comorbidities. Nevertheless, the evolution of polypharmacy in newly diagnosed males and females has been little studied.
Objective
UNASSIGNED
The objective of this paper was to identify and describe medication trajectories in incident diabetes cases according to sex.
Methods
UNASSIGNED
Data were obtained from the Quebec Integrated Chronic Disease Surveillance System. We built a population-based cohort of community-dwelling individuals aged >65 years diagnosed with diabetes in 2014 who were alive and covered with the public drug plan until March 31, 2019. Latent class models were used to identify medication trajectory groups in males and females separately.
Results
UNASSIGNED
Of the 10,363 included individuals, 51.4% were males. Females were older and more likely to have more medication claims than males. Four trajectory groups were identified for males and five for females. Most trajectories showed sustained and stable number of medications over time. For each sex, only one of the trajectory groups included a mean annual number of medications lesser than five. Slight increasing trends of medication use were detected in the trajectories composed of very high users, which included older, more comorbid individuals frequently exposed to potentially inappropriate medications.
Conclusions
UNASSIGNED
Most males and females with incident diabetes had a high burden of medication following the year of diagnosis and were classified in a group of sustained medication use over time. The largest increase in medication was among those who had higher level of polypharmacy of questionable quality at baseline, raising concerns about the innocuity of such medication trajectories.
Identifiants
pubmed: 37408840
doi: 10.1016/j.rcsop.2023.100294
pii: S2667-2766(23)00075-6
pmc: PMC10319302
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100294Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Chronic Dis Inj Can. 2014 Nov;34(4):226-35
pubmed: 25408182
Br J Clin Pharmacol. 2021 Mar;87(3):1264-1274
pubmed: 32737910
J Clin Epidemiol. 2004 Feb;57(2):131-41
pubmed: 15125622
Pharmacy (Basel). 2019 Dec 01;7(4):
pubmed: 31805662
Can J Cardiol. 2012 Mar-Apr;28(2):162-8
pubmed: 22230034
Ther Adv Cardiovasc Dis. 2022 Jan-Dec;16:17539447221113946
pubmed: 35875931
Diabetes Care. 2002 Mar;25(3):512-6
pubmed: 11874939
Expert Opin Drug Saf. 2018 Dec;17(12):1185-1196
pubmed: 30540223
Soc Psychiatry Psychiatr Epidemiol. 2017 Jul;52(7):829-836
pubmed: 27878580
Prim Care Diabetes. 2020 Oct;14(5):529-537
pubmed: 32402848
Pharmacoepidemiol Drug Saf. 2022 Jan;31(1):1-12
pubmed: 34623723
Diabetologia. 2018 Jul;61(7):1503-1516
pubmed: 29417185
Cardiovasc Diabetol. 2020 Sep 15;19(1):138
pubmed: 32933542
Eur J Clin Pharmacol. 2007 Aug;63(8):725-31
pubmed: 17554532
Adv Life Course Res. 2020 Mar;43:100323
pubmed: 36726256
J Clin Epidemiol. 1995 Aug;48(8):999-1009
pubmed: 7775999
BMJ Open. 2018 Jul 7;8(7):e020683
pubmed: 29982203
PLoS One. 2021 Apr 26;16(4):e0250567
pubmed: 33901232
Curr Med Res Opin. 2016 Jul;32(7):1243-52
pubmed: 26986190
Pharmacy (Basel). 2019 Aug 29;7(3):
pubmed: 31470621
J Manag Care Spec Pharm. 2020 Sep;26(9):1138-1152
pubmed: 32857646
Fam Pract. 2020 Mar 25;37(2):173-179
pubmed: 31602472
J Am Geriatr Soc. 2019 Apr;67(4):674-694
pubmed: 30693946
Diabet Med. 2017 Aug;34(8):1108-1115
pubmed: 28453875
Diabet Med. 2020 Oct;37(10):1688-1695
pubmed: 32531090
Chronic Dis Can. 2009;29(4):178-91
pubmed: 19804682
Diabetologia. 2019 Oct;62(10):1761-1772
pubmed: 31451872
Soc Psychiatry Psychiatr Epidemiol. 2018 Aug;53(8):869
pubmed: 29947859
Int J Environ Res Public Health. 2019 Jun 20;16(12):
pubmed: 31226874
Am J Epidemiol. 2023 Jun 29;:
pubmed: 37386696
Explor Res Clin Soc Pharm. 2021 Aug 05;3:100053
pubmed: 35480610
Health Promot Chronic Dis Prev Can. 2017 Feb;37(2):49-53
pubmed: 28273040
J Am Geriatr Soc. 2019 Jun;67(6):1123-1127
pubmed: 30697698
Chin Med J (Engl). 2018 May 20;131(10):1199-1205
pubmed: 29722339
Med Care. 2018 May;56(5):441-447
pubmed: 29578951
J Clin Epidemiol. 2002 Aug;55(8):809-17
pubmed: 12384196
Br J Clin Pharmacol. 2020 Jun;86(6):1062-1080
pubmed: 31916266
J Am Geriatr Soc. 2021 Aug;69(8):2163-2175
pubmed: 33959939
J Psychosom Res. 2018 Jan;104:95-100
pubmed: 29275792